Clinical Trial Update: Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dalteparin for primary prophylaxis of venous thromboembolism in brain tumor patients has completed; no results are provided in the upda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Venous Thromboembolism

Drugs mentioned

• Dalteparin (Fragmin) (dalteparin sodium)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Venous Thromboembolism, Brain Tumors | Phase 3 | Status: COMPLETED